• 1. Department of Clinical Pharmacology, the Affiliated Hospital (Group) of Putian University, Putian 351100, China;
  • 2. Pharmaceutical and Medical Technology College of Putian University, Putian 351100, China;
LIN Qingshuang, Email: linqingshuang1989@126.com
Export PDF Favorites Scan Get Citation

Objective  To study the correlation of changes in liver function during long-term treatment with sodium valproate (VPA) in children with epilepsy in Putian, and to explore individualized administration to improve the compliance of children with medication. Methods  The blood concentration of VPA and related biochemical test data of 350 children with epilepsy from June 1, 2018 to March 1, 2021 were collected in our hospital. According to the results of VPA blood concentration, they were classified as low Blood concentration group (<50 μg/mL), therapeutic blood concentration group (50 ~ 100 μg/mL) and high blood concentration group (>100 μg/mL). Results  There was no significant difference in liver function indexes between the VPA treatment group and the control group (P>0.05). There were significant differences in liver function ALT, AST, AST/ALT, TBIL and DBIL among the groups of VPA blood concentration range (P<0.05). The abnormal incidence of liver function indexes of high blood drug concentration was lower in the concentration group and higher in the treatment concentration group, and there were differences (P<0.05). Conclusion  Abnormal liver function in the high blood drug concentration treatment groupis quite common, and the dose of the drug should be adjusted in time to avoid liver damage caused by the VPA.

Citation: WENG Aibin, HUI Xiaoyu, LIN Qingshuang. Correlative study on the changes in liver function caused by sodium valproate in children with epilepsy. Journal of Epilepsy, 2022, 8(2): 123-126. doi: 10.7507/2096-0247.202111002 Copy

  • Previous Article

    EEG analysis of subclinical seizures in frontotemporal lobe epilepsy
  • Next Article

    Expression analysis and bioinformatics prediction of circrnas in peripheral blood mononuclear cells of epilepsy patients